


# CoNCERT Pharmaceuticals Inc.®

Concert Pharmaceuticals  
Investor Relations Department  
99 Hayden Avenue, Suite 500  
Lexington, MA 02421  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

## NASDAQ: CNCE

Last Trade:	15.14
Trade Time:	9:35 AM ET Sep 19, 2017
Change:	0.26  (+1.747%)
Day Range	15.14 - 15.48
52-Week Range	7.11 - 19.11
Volume	17,409


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

At Concert Pharmaceuticals, we are pioneering our industry-leading expertise in deuterium chemistry to discover and develop innovative drug products that have impact for patients and address important medical needs. Our innovative approach has already resulted in multiple drug candidates that offer improved ways to target a broad range of disease areas, including CNS disorders, renal disease, inflammation and cancer. Each of these novel candidates was designed to be improved with our deuterium chemistry, and is based on an approved drug, an advanced clinical candidate or a previously studied, biologically active compound.

[\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Aug 31, 2017*

[Concert Pharmaceuticals Announces Webcast at Wells Fargo Healthcare Conference](#)

*Aug 8, 2017*

[Concert Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Company Update](#)

*Aug 1, 2017*

[Concert Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017](#)

*Jul 25, 2017*

[Vertex and Concert Pharmaceuticals Complete Asset Purchase Agreement for CTP-656](#)

*Jul 24, 2017*

[Concert Pharmaceuticals Announces Termination of the HSR Act Waiting Period for CTP-656 Asset Purchase Agreement with Vertex](#)

## Upcoming Events [\[ View all \]](#)

*Nov 14–15, 2017*

[2017 Stifel Healthcare Conference](#)

*Dec 4–5, 2017*

[Global Mizuho Investor Conference NY](#)

## Financials [\[ View all \]](#)

*Apr 26, 2017*

[Proxy Statement \(DEF 14A\)](#)

*Aug 8, 2017*

[Quarterly Report \(10-Q\)](#)

*May 2, 2017*

[Quarterly Report \(10-Q\)](#)